Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression.

This post hoc analysis found that both short and long-term treatment with lurasidone was associated with a relatively low risk for the development of MetS in patients with bipolar I disorder. These findings are consistent with similar analyses in patients with schizophrenia.